BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38184773)

  • 21. 5hmC Immunohistochemistry: A Predictor of
    Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
    J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Performance of Ultrasound Patterns by K-TIRADS and 2015 ATA Guidelines in Risk Stratification of Thyroid Nodules and Follicular Lesions of Undetermined Significance.
    Hong HS; Lee JY
    AJR Am J Roentgenol; 2019 Aug; 213(2):444-450. PubMed ID: 31039023
    [No Abstract]   [Full Text] [Related]  

  • 23. ACR TI-RADS classification combined with number of nodules, halo features optimizes diagnosis and prediction of follicular thyroid cancer.
    Wu SJ; Tan L; Ruan JL; Qiu Y; Hao SY; Yang HY; Luo BM
    Clin Hemorheol Microcirc; 2022; 82(4):323-334. PubMed ID: 36093690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Korean Thyroid Imaging Reporting and Data System features of follicular thyroid adenoma and carcinoma: a single-center study.
    Park JW; Kim DW; Kim D; Baek JW; Lee YJ; Baek HJ
    Ultrasonography; 2017 Oct; 36(4):349-354. PubMed ID: 28494523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of current ultrasound-based malignancy risk stratification systems for thyroid nodules in patients with follicular neoplasms.
    Lin Y; Lai S; Wang P; Li J; Chen Z; Wang L; Guan H; Kuang J
    Eur Radiol; 2022 Jun; 32(6):3617-3630. PubMed ID: 34973102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.
    Matsuura D; Yuan A; Wang L; Ranganath R; Adilbay D; Harries V; Patel S; Tuttle M; Xu B; Ghossein R; Ganly I
    Thyroid; 2022 Mar; 32(3):245-254. PubMed ID: 35078345
    [No Abstract]   [Full Text] [Related]  

  • 27. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
    Cracolici V; Ritterhouse LL; Segal JP; Puranik R; Wanjari P; Kadri S; Parilla M; Cipriani NA
    Am J Surg Pathol; 2020 Jul; 44(7):881-892. PubMed ID: 32282345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Sonographic Features of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features: A Retrospective Study.
    Ni X; Xu S; Zhang B; Zhan W; Zhou W
    Ultrasound Q; 2023 Mar; 39(1):23-31. PubMed ID: 35001029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasonographic features for differentiating follicular thyroid carcinoma and follicular adenoma.
    Kuo TC; Wu MH; Chen KY; Hsieh MS; Chen A; Chen CN
    Asian J Surg; 2020 Jan; 43(1):339-346. PubMed ID: 31182260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.
    Lo CY; Chan WF; Lam KY; Wan KY
    Ann Surg; 2005 Nov; 242(5):708-15. PubMed ID: 16244545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
    Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
    Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microarray analysis of formalin-fixed, paraffin-embedded follicular thyroid carcinoma samples from patients who developed postoperative distant metastasis.
    Jikuzono T; Ishikawa T; Hirokawa M; Sugitani I; Ishibashi O
    BMC Res Notes; 2020 May; 13(1):241. PubMed ID: 32404135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
    Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
    Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasonographic characteristics of medullary thyroid carcinoma according to nodule size: application of the Korean Thyroid Imaging Reporting and Data System and American Thyroid Association guidelines.
    Hahn SY; Shin JH; Oh YL; Park KW
    Acta Radiol; 2021 Apr; 62(4):474-482. PubMed ID: 32493032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
    Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.